Research programme: haematopoietic stem cell therapies - EdiGene/Institute of Hematology and Blood Diseases Hospital
Latest Information Update: 10 Feb 2022
At a glance
- Originator EdiGene Inc; Institute of Hematology & Blood Diseases Hospital
- Class Antineoplastics; Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders; Cancer; Inborn genetic disorders